在与CYP3A/P-gp调节剂联合使用时,对Valemetostat的生理基础的药理动力学建模以告知剂量建议
Akiko Watanabe1, Noriko Okudaira2, Masaya Tachibana1
1Daiichi Sankyo Co., Ltd., Tokyo, Japan.
瓦莱梅托斯被CYP3A代谢,并通过P-gp分泌. 一个经过验证的PBPK模型预测了药物相互作用,有助于调整服用valemetostat和其他药物的患者的剂量.
科学领域:
- 药理学 药理学 是一个学科.
- 药物新陈代谢 药物新陈代谢
- 药理动力学 药理动力学
背景情况:
- 瓦莱梅托斯酸是一种口服双抑制剂,用于治疗T细胞白血病.
- 瓦莱梅托斯塔特通过CYP3A进行了系统前代谢,并通过P-gp排出.
研究的目的:
- 开发和验证一个基于生理学的药理动力学 (PBPK) 模型,用于valemetostat.
- 预测CYP3A和P-gp调节剂对瓦莱梅托斯塔特药理动学的影响.
主要方法:
- 使用体外和临床PK数据构建了一个PBPK模型.
- 该模型与用可纳,伊特拉可纳和利芬素进行的药物相互作用研究进行了验证.
主要成果:
- 该PBPK模型准确地描述了肠道和肝脏中CYP3A和P-gp对valemetostat PK的贡献.
- 该模型成功预测了CYP3A/P-gp抑制剂和诱导剂对瓦莱梅托斯塔特PK的影响.
结论:
- 经过验证的PBPK模型有效地估计了CYP3A和P-gp调节器对瓦莱美托斯PK的影响.
- 这种PBPK模型可以指导与其他药物同时使用valemetostat的剂量建议.
更多相关视频
07:23Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
Published on: October 20, 2023
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Dosage Regimens: Partial Pharmacokinetic Parameters
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Model Approaches for Pharmacokinetic Data: Physiological Models
